-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Earlier, Regeneron And Sanofi's Dupixent Demonstrates Statistically Superior Efficacy Over Xolair In Nasal Polyps And Lung Function In Patients With Coexisting Asthma

Benzinga·06/16/2025 07:36:22
Listen to the news
  • New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints
  • Dupixent also outperformed Xolair in improving such key signs and symptoms as nasal polyp size and sense of smell in CRSwNP, and lung function and disease control in asthma, with rapid improvements seen as early as 4 weeks
  • Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation